Sprenger GP, Roos RAC, van Zwet E, et al. - Researchers conducted a large worldwide study to determine the prevalence of pain interference, painful conditions and analgesic use across the different stages of Huntington Disease (HD). In addition, they compared these levels to non-HD gene mutation carriers. Premanifest, manifest HD gene mutation carriers (n = 3,989 and n = 7,485, respectively) and non-HD gene mutation carriers (n = 3,719) were assessed in this cross-sectional analysis of the Enroll-HD study. An increase in the prevalence of pain interference occurs with progression of HD, however, the prevalence of painful conditions and analgesics do not increase accordingly. In the middle stage of HD, an increase in the prevalence of pain interference was observed up to 42%. As HD progresses, decrease in the prevalence of painful conditions and analgesic use is noted. The reports of some painful conditions and analgesics change as HD progresses.